Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open Label，Single Arm，Phase Ib/II Study to Evaluate the Effect and Safety of RC48-ADC Combined With S-1 for First-line Treatment of Advanced Gastroesophageal Adenocarcinoma With Moderate Expression of HER2

NCT05403242 is registered in ClinicalTrials.gov with Chinese PLA General Hospital as lead sponsor.

NCT NCT05403242
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05403242 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open Label，Single Arm，Phase Ib/II Study to Evaluate the Effect and Safety of RC48-ADC Combined With S-1 for First-line Treatment of Advanced Gastroesophageal Adenocarcinoma With Moderate Expression of HER2
Lead sponsor
Chinese PLA General Hospital
Phase
Phase 1/2
Overall status
Recruiting
Start date
September 20, 2022
Completion date
September 30, 2026
Enrollment
42 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advanced gastroesophageal adenocarcinoma